U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis
  1. Drug Safety and Availability

Due to risk of serious liver injury, FDA restricts use of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis

Adding and updating warnings

en Español

Drug Safety Communication (PDF - 154 KB) 

05-26-2021  FDA Drug Safety Communication

Related Information

Contact FDA

For More Info
855-543-DRUG (3784) and press 4
druginfo@fda.hhs.gov

Report a Serious Problem to MedWatch
Complete and submit the report Online.
Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Back to Top